Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
8 papers
Recent·Most cited
C. Barelli, F. Kaluthantrige Don, R. M. Iannuzzi, I. Bertani, I. Osei, S. Sorrentino, G. Villa, V. Sokolova, F. Iorio, N. Kalebic
The paper identifies ADD3 as a regulator of glioblastoma stem cell morphology and tumor-tumor connections, showing its role in proliferation and survival.
bioRxiv · Mar 26, 2024Cell Biology
R. Angioni, M. Bonfanti, N. Caporale, R. Sanchez-Rodriguez, F. Munari, A. Savino, D. Buratto, I. Pagani, N. Bertoldi, C. Zanon, P. Ferrari, E. Ricciardelli, C. Putaggio, S. Ghezzi, F. Elli, , G. Testa
The paper identifies RAGE as a novel receptor for SARS-CoV-2 that mediates monocyte infection and contributes to COVID-19 severity through single-cell analysis of immune responses.
bioRxiv · May 22, 2022Immunology
T. Heide, J. Househam, G. D. Cresswell, I. Spiteri, C. Lynn, C. Kimberley, M. Mossner, L. Zapata, C. Gabbutt, D. Ramazzotti, B. Chen, J. Fernandez-Mateos, C. James, F. Iorio, A. Berner, , A. Sottoriva
This study uses spatial multiomic data to assess the evolutionary impact of putative driver mutations in colorectal cancer, identifying both genetic and non-genetic factors influencing subclonal expansion.
bioRxiv · Jul 14, 2021 · PreprintCancer Biology
J. M. Dempster, C. Pacini, S. Pantel, F. M. Behan, T. Green, J. Krill-Burger, C. M. Beaver, S. T. Younger, V. Zhivich, H. Najgebauer, F. Allen, E. Goncalves, R. Shepherd, J. G. Doench, K. Yusa, , A. Tsherniak
This study compares two large pan-cancer CRISPR-Cas9 screens, finding high concordance in gene dependencies despite differences in protocols and reagents.
bioRxiv · Jun 4, 2019Cancer Biology
M. Garnett, G. Picco, E. Chen, L. Garcia Alonso, F. Behan, E. Goncalves, G. Bignell, A. Matchan, B. Fu, R. Banerjee, E. Anderson, A. Butler, C. Benes, U. McDermott, D. Dow, , J. Saez-Rodriguez
The paper functionally links gene fusions to cancer cell fitness using drug sensitivity and CRISPR-Cas9 data, identifying rare functional fusions and novel therapeutic targets.
bioRxiv · Feb 24, 2019Cancer Biology
F. M. Behan, F. Iorio, E. Goncalves, G. Picco, C. M. Beaver, R. Santos, Y. Rao, R. Ansari, S. Harper, D. A. Jackson, R. McRae, R. Pooley, P. Wilkinson, D. Dow, C. Buser-Doepner, , G. J. Mathew
This study uses CRISPR-Cas9 screens in cancer cell lines to identify and prioritize new oncology therapeutic targets based on gene fitness, biomarkers, and tractability.
bioRxiv · Dec 20, 2018Cancer Biology
T. Cokelaer, E. Chen, F. Iorio, M. P. Menden, H. Lightfoot, J. Saez-Rodriguez, G. J. Mathew
GDSCTools provides a software package for analyzing pharmacogenomic data to identify genomic markers of drug response in cancer.
bioRxiv · Jul 28, 2017Cancer Biology
L. Garcia-Alonso, F. Iorio, A. Matchan, N. Fonseca, P. Jaaks, F. Falcone, G. Bignell, S. S. McDade, M. J. Garnett, J. Saez-Rodriguez
The paper uses computational methods to infer transcription factor activities from RNA-seq data and shows their utility as markers for drug response in cancer.
bioRxiv · Apr 21, 2017Cancer Biology